Diagnostic usefulness of 18F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 11, 2013, Pages 1692-1700

  Nobusawa, Aiko ^a   Kim, Mai ^a   Kaira, Kyoichi ^a,b   Miyashita, Go ^a   Negishi, Akihide ^a   Oriuchi, Noboru ^a   Higuchi, Tetsuya ^a   Tsushima, Yoshito ^a   Kanai, Yoshikatsu ^c   Yokoo, Satoshi ^a   Oyama, Tetsunari ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

LAT1; Oral cancer; Squamous cell carcinoma

Indexed keywords

AMINO ACID TRANSPORTER; BIOLOGICAL MARKER; CD34 ANTIGEN; CD98 ANTIGEN; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; L TYPE AMINO ACID TRANSPORTER 1; METIROSINE; PROTEIN P53; UNCLASSIFIED DRUG; 3 FLUORO ALPHA METHYLTYROSINE; 3-FLUORO-ALPHA-METHYLTYROSINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CAPILLARY DENSITY; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PET SCANNER; PREDICTIVE VALUE; PRIMARY TUMOR; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; GENETICS; METABOLISM; MIDDLE AGED; MOUTH TUMOR; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; DIAGNOSTIC USE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MALE; METHYLTYROSINES; MIDDLE AGED; MOUTH NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84885423533     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2477-9     Document Type: Article

References (34)

1. Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010;28:3746-53.
2. Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, et al. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012;48:1244-54.
3. Kaira K, Oriuchi N, Otani Y, Yanagitani N, Sunaga N, Hisada T, et al. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest. 2007;131:1019-27.
4. Tomiyoshi K, Amed K, Muhammad S, Higuchi T, Inoue T, Endo K, et al. Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun. 1997;18:169-75.
5. Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, et al. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med. 2012;53:1253-61.
6. Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13:6369-78.
7. Inoue T, Shibasaki T, Oriuchi N, Aoyagi K, Tomiyoshi K, Amano S, et al. 18F-α-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med. 1999;40:399-405.
8. Miyashita G, Higuchi T, Oriuchi N, Arisaka Y, Hanaoka H, Tominaga H, et al. 18F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with 18F-FDG PET and immunohistochemistry. Ann Nucl Med. 2010;24:579-84.
9. Sohda M, Kato H, Suzuki S, Tanaka N, Sano A, Sakai M, et al. 18F-FAMT-PET is useful for the diagnosis of lymph node metastasis in operable esophageal squamous cell carcinoma. Ann Surg Oncol. 2010;17:3181-6.
10. Isoda A, Higuchi T, Nakano S, Arisaka Y, Kaira K, Kamio T, et al. 18F-FAMT in patients with multiple myeloma: clinical utility compared to 18F-FDG. Ann Nucl Med. 2012;26:811-6.
11. Miyakubo M, Oriuchi N, Tsushima Y, Higuchi T, Koyama K, Arai K, et al. Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med. 2007;21:129-35.
12. Watanabe H, Inoue T, Shinozaki T, Yanagawa T, Ahmed AR, Tomiyoshi K, et al. PET imaging of musculoskeletal tumours with fluorine-18 alpha- methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med. 2000;27:1509-17.
13. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273:23629-32.
14. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514:291-302.
15. Nakanishi K, Ogata S, Matsuo H, Kanai Y, Endou H, Hiroi S, et al. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2007;451:681-90.
16. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 2006;119:484-92.
17. Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, et al. L-type amino acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int. 2009;59:7-18.
18. Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, et al. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int. 2011;61:281-9.
19. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008;98:742-8.
20. Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 2012;103:382-9.
21. Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 2012;107:632-8.
22. Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, et al. LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res. 2011;3:468-78.
23. Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, et al. Evaluation of thoracic tumors with 18F-FMT and 18F-FDG PET-CT: a clinicopathological study. Int J Cancer. 2009;124:1152-60.
24. Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, et al. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med. 2009;50:1770-6.
25. Pauleit D, Zimmermann A, Stoffels G, Bauer D, Risse J, Flüss MO, et al. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med. 2006;47:256-61.
26. Sutinen E, Jyrkkiö S, Alanen K, Någren K, Minn H. Uptake of [N-methyl-11C]alpha-methylaminoisobutyric acid in untreated head and neck cancer studied by PET. Eur J Nucl Med Mol Imaging. 2003;30:72-7.
27. Troost EG, Vogel WV, Merkx MA, Slootweg PJ, Marres HA, Peeters WJ, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-35.
28. Krabbe CA, van der Werff-Regelink G, Pruim J, van der Wal JE, Roodenburg JL. Detection of cervical metastases with 11C-tyrosine PET in patients with squamous cell carcinoma of the oral cavity or oropharynx: a comparison with 18F-FDG PET. Head Neck. 2010;32:368-74.
29. Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Expression of Glut1 and Glut3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging. 2004;31:5-12.
30. Li SJ, Guo W, Ren GX, Huang G, Chen T, Song SI. Expression of Glut-1 in primary and recurrent head and neck squamous cell carcinomas, and compared with 2-[18F]fluoro-2-deoxy-D-glucose accumulation in positron emission tomography. Br J Oral Maxillofac Surg. 2008;46:180-6.
31. Han MW, Lee HJ, Cho KJ, Kim JS, Roh JL, Choi SH, et al. Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck. 2012;34:1395-402.
32. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2006;15:254-66.
33. Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, et al. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res. 2010;30:4819-28.
34. Kim CS, Cho SH, Chun HS, Lee SY, Endou H, Kanai Y, et al. BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull. 2008;31:1096-100. Technology